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ROLE OF THE THROMBOSPONDIN - CD36 - HISTIDINE RICH
GLYCOPROTEIN PATHWAY IN TUMOR GROWTH AND ANGIOGENESIS
JAMES SCOTT HALE
ABSTRACT
Cancer is typically thought of as an uncommon disease, in which solid tumors
require a blood supply in order to grow and metastasize. Interestingly, upon autopsy a
large portion of elderly individuals display numerous non-vascularized lesions
throughout their bodies. Thus, the angiogenic switch in the development of cancer
presents an important therapeutic target. Previous work by our laboratory has established
an interaction between CD36, Histidine Rich Glycoprotein (HRGP) and Thrombospondin
1 (TSP-1) in the modulation of angiogenesis. Briefly, endothelial cell receptor CD36
interaction with soluble or cell bound TSP-1 leads to the induction of an apoptotic
signaling cascade in vascular endothelial cells resulting in decreased proliferation,
migration and tube formation, thereby inhibiting angiogenesis. Presence of soluble
HRGP leads to inhibition of the anti-angiogenic potential of the CD36-TSP-1 pathway
through a decoy receptor function whereby TSP-1is bound and sequestered. Previous
studies have focused on this pathway with regards to wound healing. However,
pathologically relevant modulation of angiogenesis is also observed in tumors. In the
current work we evaluate the role of the CD36-TSP-HRGP pathway in tumor growth and
angiogenesis. Further, we examine a possible processing mechanism by which TSP
function may be modulated by a matrix metalloprotease, ADAMTS1.
Chapters two through five will outline the role of the TSP-CD36 axis in tumor
biology, namely angiogenesis and growth. We will also address modulation of this
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pathway via HRGP. Further we will describe a matrix metalloprotease mechanism by
which TSP function may be regulated.
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CHAPTER I
INTRODUCTION
Cancer Overview
Cancer as defined by the American Cancer Society is a group of diseases
characterized by the uncontrolled growth of abnormal cells, which if not restricted may
result in death1. Extrinsic/environmental factors including UV radiation, tobacco use and
chemical exposure and intrinsic factors such as immune function, genetic background and
hormone levels may cause or hasten the induction of cancerous lesions2,3,4,5,6,7. This
group of diseases is now recognized as one in which multiple genetic “hits” or mutations
are required for initiation.
These mutations result in the induction of oncogenes or inhibition of tumor
suppressor genes. Proto-oncogenes are normal genes that may become oncogenes upon
mutation or over-expression. These genes encode proteins that regulate cell division and
growth and include RAS, WNT, MYC and ERK8,9. Tumor suppressor genes are native
genes that regulate cell division, repair deoxyribonucleic acid (DNA) and control
apoptosis (controlled cell death). Upon mutation, these genes are inhibited resulting in
decreased action and uncontrolled cell growth. Common tumor suppressor genes include
p53, BRCA1, APC and RB110. It is through a combination of oncogene activation an
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tumor suppressor inhibition that cells may acquire the mutations necessary to take on a
malignant phenotype and initiate cancer.
These mutations result in a set of functional capabilities better known as the
hallmarks of cancer, as proposed by Hanahan and Weinberg11. This includes evasion of
apoptosis, self sufficiency in growth signals, insensitivity to anti-growth signals, limitless
replicative potential, sustained angiogenesis and tissue invasion and metastasis. These
functional capabilities allow cells to break free from the constraints of their
microenvironment resulting in uninhibited growth and the formation of cancerous
lesions.
Disease Statistics and Treatments
The American Cancer Society estimates that males in the United States have a 1
in 2 chance of developing cancer over their lifetime, with females experiencing a lower
rate of 1 in 3. Cancer is the second leading cause of death in the United States, behind
heart disease. Further, for 2011 it is anticipated that 571,950 individuals will die as a
result of cancer with an additional 1,596,670 new cases being diagnosed1.
Currently, there are numerous therapeutic strategies for cancer as a whole. Most
often these strategies are used in concert rather than individually. These include resection
of the cancerous lesion (at this time the only effective strategy for melanomas)12,
radiation therapy (more specifically ionizing radiation which dislodges electrons leading
to cell death)13, chemotherapy (in which injected or ingested antimetabolites or inhibitors
lead to cell death in rapidly dividing cells)14, immunotherapy (where the hosts immune
system is activated by manufactured antibodies or vaccines, gardasil for example to
prevent cervical cancers)15, photodynamic therapy (most often used with skin cancers
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whereby light causes a photosensitizing agent to interact with oxygen and produce free
radicals toxic to the cell)16, thermal therapies (in which heat or cold are used to destroy
small areas of cells)17,18 and lastly anti-angiogenic therapies (which take two forms,
destruction of existing vessels or prevention of the formation of new ones).
Unfortunately, the majority of these therapies are relatively nonspecific, targeting
both healthy host and tumor tissue. As such, there is an urgent need for treatments based
on molecular pathways or specific antigens, some of which are more prevalent in
individual cancers; breast cancer 1 (BRACA1) in breast cancer and melanoma and
adenomatous polyposis coli (APC) in colon cancer for example. Significant strides have
been made utilizing the genomic approach of cancer treatment; we will focus on several
advancements in targeted cancer treatment with regards to angiogenic modulation.
In 1999, the National Cancer Institute marked the development of angiogenic
inhibiting cancer therapies as an urgent priority. Following, in 2004, Bevacizumab, a
humanized monoclonal antibody against VEGF, better known as Avastin became the first
anti-angiogenic compound approved by the FDA for the treatment of cancer19. As of
March 2011, four anti-angiogenic drugs have been approved by the FDA, all of which
target the vascular endothelial growth factor (VEGF) pathway20.
Currently, several angiogenesis inhibitors are in phase III clinical trials for varied
human cancers including melanoma, breast and gastric cancer21. Trial NCT00111007 is
currently examining the use of Sorafenib in combination with chemotherapeutics
Paclitaxel and Carboplatin in the treatment of Stage III and IV melanoma. Sorafenib is a
kinase inhibitor shown to inhibit angiogenesis through the induction of endothelial cell
apoptosis22. Trial NCT01303679 is currently evaluating the use of Avastin in
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combination with chemotherapeutics Taxane and Exemestane in the treatment of
metastatic breast cancer. Avastin is currently under study in approximately one dozen
additional phase III clinical trials. Trial NCT01170663 is currently evaluating the use of
Ramucirumab in combination with chemotherapeutic paclitaxe in the treatment of gastric
carcinoma. Ramucirumab is a human monoclonal VEGFR2 activating antibody. It is
one of two making use of Ramucirumab, with a third examining Avastin.
These trials use a combinatorial approach, targeting the vasculature along with the
rapidly dividing tumor cell population. Despite the promise these trials present, we
should not “put all our eggs in one basket”. As such, additional avenues of angiogenic
modulation should be examined.
Angiogenesis and Cancer
Angiogenesis is the physiologic process by which new vessels sprout from the
existing vasculature. In 1907 the association of the vasculature and solid tumors was first
described23. However, the field of angiogenic research did not begin until 1971 with the
publication of work by Judah Folkman hypothesizing the growth of neoplastic lesions
was dependent on angiogenesis24, which has since been validated in numerous tumor
types including those originating in the brain, breast, prostate, skin and lung25,26,27,28,29.
In the normal adult setting, the vasculature is maintained in a quiescent state
through a balance of angiogenic inhibitors, such as Thrombospondin 1 (TSP), and
inducers, such as VEGF. This balance between pro- and anti-angiogenic stimuli is
important in homeostasis, in particular in such conditions as pregnancy and wound
healing. Loss of homeostatic balance resulting in excessive or insufficient angiogenesis
has been implicated in numerous diseased states such as ulcerative colitis, diabetic
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retinopathy, obesity, psoriasis, rheumatoid arthritis, stroke, coronary artery disease and
cancer30,31,32,33,34,35,36.
Interestingly, most apparently healthy individuals display numerous small
nonvascularized lesions throughout their bodies. However, only approximately 1 in 600
of these small, quiescent tumors will acquire an angiogenic phenotype resulting in a
clinically detectable cancer37. Supporting this observation, it is well established that solid
tumors will grow to 1-2 mm by simple diffusion but require a blood supply in order to
expand further and metastasize. To this end tumors express pro-angiogenic substances
such as basic fibroblast growth factor (bFGF) and VEGF which recruit blood vessels to
the lesion through the induction of endothelial cell proliferation migration and tube
formation (Figure 1).

Figure 1. Tumor vessel recruitment. Tumors will grow to a limited volume through diffusion, 1-2 mm.
In order to expand further they secrete angiogenic compounds, such as VEGF, allowing for the recruitment
of blood vessels and subsequent growth and metastasis (Genentech).

Cardiovascular Structure
The cardiovascular system supplies our tissues with oxygen and nutrients as well
as collecting and expelling carbon dioxide (CO2). Most cells of the body are located
within 200 µm of a blood vessel, the diffusible limit for oxygen38. The heart is the engine
that drives blood flow throughout the body. Deoxygenated blood enters the right atrium
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of the heart through the superior and inferior vena cava. The blood then moves to the
right ventricle where it is pumped into the pulmonary artery and capillary beds of the
lungs. Here, oxygen is exchanged for CO2 collected from the body tissues. The oxygen
enriched blood then enters left atrium through the pulmonary vein. The flow of blood
continues into the left ventricle where it leaves the heart via the aorta and enters systemic
circulation, supplying the tissues of our body with oxygen and absorbing carbon dioxide
through a complex capillary network. This network ends with the venous system which
returns deoxygenated blood to the heart39.
The vasculature consists of three types of vessels; arteries which carry oxygen
rich blood from the heart, capillaries where gas, nutrient and waste exchange occurs and
veins which return blood to the heart. Arteries and veins are similar in structure
consisting of three layers; tunica intima, tunica media and tunica adventitia. The
innermost tunica intima consists of an endothelium, a layer of simple squamous
endothelial cells, with an associated basement membrane. Surrounding this layer is the
tunica media made up of smooth muscle cells and elastic connective tissue and is
responsible for vasodilation and vasoconstriction. The tunica adventitia encapsulates the
tunica media in a layer of collagen, thereby acting as an anchor with the surrounding
tissue40.
The capillary network is structurally unique and allows for efficient exchange of
materials. These vessels are the smallest of the vascular system and consist of a single
layer of endothelial cells surrounded by a basement membrane. These vessels are the site
at which angiogenesis typically occurs.
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Steps of Angiogenesis
As stated previously, the vasculature is normally maintained in a quiescent state.
In instances where pro-angiogenic stimuli predominate angiogenesis occurs through the
induction of micro-vascular endothelial cells. In response to pro-angiogenic stimuli, such
as VEGF, selective sprouting of endothelial cells from the existing vasculature is
observed (Figure 2). This involves the disruption of cell-cell junctions, a reversal of cell
polarity and increased protease expression, allowing for extracellular matrix degradation.
This is followed by sprout expansion and directional chemotaxis. During this period,
microvascular endothelial cells proliferate and migrate along pro- and inhibitory
angiogenic gradients, achieving polarized extension of the sprout. As the sprout extends,
extracellular matrix is deposited and pericytes are recruited to stabilize the forming vessel
which fuses with the existing vasculature. Subsequent steps are poorly understood.
Endothelial cell-cell interactions are maintained in the maturing vessel as vacuoles form
and fuse first intracellularly and subsequently intercellularly, resulting in the formation of
a primitive lumen. Following lumen formation blood flow is established. (41)

Figure 2. Angiogenic vessel sprouting. In response to pro-angiogenic signaling endothelial cells reverse
polarity, secrete matrix degrading enzymes and begin to migrate along the stimulus gradient. As the newly
formed vessel matures, basement membrane is layered down and associated cells such as vascular smooth
muscle cells and fibroblast stabilize the growing structure (Genentech).
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Thrombospondin - CD36 - Histidine Rich Glycoprotein Axis
Thrombospondin -1
Numerous reports have shown reduction or blockade of tumor growth by
inhibition of angiogenesis. Thrombospondin-1(TSP) (Figure 3), in 1978, was the first
endogenous anti-angiogenic molecule to be identified (42-44). The thrombospondin
family consists of five extracellular calcium binding members (Thrombospondins 1-5) of
which Thrombospondin-1 and 2 are most structurally similar (45, 46). TSP, like
Thrombospondin 2, is a 450 kDa trimeric multi-domain matricellular glycoprotein.

-Amino

-Procollgen

-Type I
-Type II

-Type III

C Terminal
Figure 3. Thrombospondin 1 structure. Proposed crystal structure of Thrombospondin 1 trimer. From left;
amino terminal domain, procollagen domain, type I repeats, type II repeats, type III repeats and carboxy terminal
domain. (Mosher 2008)

Each monomer consists of, in order, an amino terminal heparin binding domain,
procollagen homology domain, three properdin like type one repeats (TSRs), three
epidermal growth factor like type 2 repeats, five calcium binding or type 3 repeats and a
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lectin like carboxy terminal domain. Monomers are connected via disulfide bonds
between the amino terminal and heparin binding domains47. TSP is expressed by several
cell types including endothelial cells48, smooth muscle cells49, fibroblasts50 and
monocytes/macrophages51 but contained primarily in platelet alpha granules, at a
concentration of 82.6 ng/106 platelets, allowing for deposition at sites of injury or
inflammation52. TSP may be soluble or cell bound, circulating in the plasma, at a
concentration of 491 ng/ml52, and incorporated into the extracellular matrix through
interaction with fibrinogen53, fibronectin54, collagen55, integrins56 and heparin sulfate57.
TSP has been implicated in diverse cellular functions and processes including
synaptogenesis, inflammation/immune function, thrombosis and angiogenesis.

The

effects on synapse formation have been localized to the type 2 repeats of TSP, with null
mice showing decreased synapse density58,59. Modulation of immune function and
inflammation by TSP is complex, involving multiple cell types with differential effects in
each. Activation of latent TGFβ by the RFK amino acid sequence of the TSRs of TSP,
which Thrombospondin 2 lacks, is thought to influence monocyte/macrophage
chemotaxis60,61. The process by which TSP activates latent TGFβ is currently unknown.
Interaction of the C-terminal domain of TSP with membrane receptor CD47 on dendritic
cells suppresses cytokine production, decreasing T-cell activation62,63. Additionally,
direct interaction of TSP with T-cell integrin enhances adhesion and recruitment64. With
regards to thrombosis, TSP has been shown to act as a bridge between platelets, binding
surface integrins, thereby promoting aggregation65. Further, TSP has been shown to
protect von Willebrand factor expressed by endothilal cells from matrix metalloprotease
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cleavage at inflammatory sites thereby enhancing platelet recruitment65. These effects
highlight the importance of TSP in tissue modeling and wound healing.
TSP is most well known as a vascular mediator. The role of TSP in vascular
function centers around two concepts; control of vascular tone and regulation of
angiogenesis. Control of vascular tone has been assessed by work by Isenberg and
Roberts who have demonstrated nitric oxide (NO) modulation of vascular smooth muscle
and endothelial cell function. NO effectively dilates vessels allowing for increased fluid
extravasation into the surrounding tissues. Additionally, NO induces endothelial cell
proliferation and migration. Two receptors, CD47 and CD36 have been implicated in
vascular NO modulation by TSP66. CD47 was further shown to be necessary for TSP
inhibition of NO signaling, with CD36 being only sufficient, therefore serving a possible
supporting function67. More rigorous study is required to further delineate the TSP
related functions of CD47 and CD36.
TSP is typically thought of as an angiogenic inhibitor, however groups have
reported pro-angiogenic functions. Work by Aharonov showed a pro-angiogenic effect
of TSP through the activation and recruitment of granulocytes in the rabbit cornea68.
Additionally, in vitro rat aortic ring models showed recruitment of myofibroblasts by
TSP, which promote angiogenesis through the secretion of heparin binding proteins69.
These data do not necessarily conflict with the reported anti-angiogenic effect of TSP
centered on microvascular endothelial cells as they focus on additional cell types.
The anti-angiogenic effects of TSP have been well characterized both in vitro and
in vivo. TSP inhibits microvascular endothelial cell proliferation, migration and tube
formation in response to basic fibroblast growth factor (bFGF) through the induction of
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apoptosis70,71. Further, TSP inhibits vascularization in response to bFGF in corneal
micropocket and subcutaneous matrigel assays70,72. Overexpression of TSP in the skin of
transgenic mice results in decreased vascularization in full thickness skin wound healing
models73. TSP overexpression in the skin has also been shown to inhibit angiogenesis
and growth of squamous cell carcinoma tumors74. Conversely, TSP null mice display
lengthened vascularization times in wound healing models and increased volume and
vessel size in spontaneous breast cancer tumors75,76.
From these studies, it appears TSP may function to both block and induce
angiogenesis, possibly allowing for fine tuned modulation of vessel formation. Inhibition
of angiogenesis in endothelial cells may be overcome by induction of pro-angiogenic
stimuli by TSP in other cell types, i.e. granulocytes and myofibroblasts. This interplay
and the role of TSP in pro-angiogenic induction require further study.
The anti-angiogenic effects of TSP have been localized to the TSRs. Treatment
of microvascular endothelial cells with recombinant TSR induces apoptosis77.
Additionally, TSR treatment effectively inhibits xenograft tumor growth and
vascularization77,78. Each TSR assumes a unique 3 stranded anti-parallel barrel structure.
The second and third strands form regular beta sheets, with the first strand possessing a
novel “rippled” structure. The strand side chains of alternating Cysteine - Arginine Tryptophan layers intercalate with one another and form the center of the structure.
Exposed side chains of the arginine and tryptophan residues result in an overall positive
charge on the binding face of this domain, which is recognized by the negatively charged
binding site on CD3679. In addition to overall charge interaction between the TSRs and
CD36, blocking antibodies and peptides have shown the amino acid sequence CSVTCG
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of TSRs is vital to this interaction80,81. Work is currently under way by our group to
solve the crystal structure of the TSR-CD36 interaction.
From the studies outlined for TSP we begin to appreciate its role in vascular
functioning, i.e. inflammation, thrombosis, vessel dilation and angiogenesis. With
regards to angiogenesis, several areas require further clarification. These include the
angiogenic duality of TSP, role of CD36 in TSP function, both in normal and pathologic
settings (i.e. tumor angiogenesis and formation), and evaluation of the overlapping roles
of TSP receptors CD47 and CD36.
CD36
CD36, first described as glycoprotein IV, is a highly glycosylated 88 kDa class B
scavenger receptor, referring to its 2 transmembrane domains, expressed on numerous
vascular cell types including platelets, macrophages and microvascular endothelial cells
(Figure 4)82,83. CD36 localizes to cholesterol-sphingolipid-rich rafts on the cellular
membrane. These domains are known to be sites of signal transduction in eukaryotic
cells84.
CD36 recognizes ligands in a cell type specific manner, possibly due to
differential co-receptor expression; CD9, α6β1, TLR2 and VEGFR2 in endothelial cells
(85, 86, 87). Immunoprecipitation and immunofluorescent colocalization were utilized to
show interaction. These studies have demonstrated modulation of TLR2 and VEGR2
signaling by CD36 and TSP. No evidence for modulation of the anti-angiogenic
interaction of CD36 and TSP has been reported. With regards to endothelial cell biology,
co-receptor expression presents a mechanism by which the inherent anti-angiogenic
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potential of CD36 may be modulated. Further study is required to evaluate the role of
these coreceptors in CD36 – TSP angiogenic functioning.

Figure 4. Membrane receptor CD36 structure. This receptor possesses two transmembrane domains,
three disulfide linkages and multiple extracellular ligand binding domains. It localizes to lipid rich rafts on
the cellular membrane (shaded). Modifications inc include intracellular palmitoylation and extracellular
glycosylation (Silverstein 2009).

On platelets, CD36 interaction with several ligands, including oxidized low
density lipoprotein lowers threshold activation. A recent study highlighted this effect
showing correlation between human platelet CD36 expression and increased sensitivity to
agonists, such as Adenosine diphosphate (ADP), resulting in increased aggregation and
alpha granule release. Further, these affects are absent in mice null for CD36. As such,
this study implicates CD36 in thrombosis and inflammation, serving as a potential marker
for thrombotic risk88.
On monocytes and macrophages, CD36 acts as a scavenger/ pattern recognition
receptor mediating pathogen phagocytosis in which it recognizes lipid and lipoprotein
moieties of bacterial origin87. This recognition involves a co-receptor function with toll
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like receptor 2/6 heterodimer (TRL2/6). Additionally, CD36 binds and mediates the
uptake of apoptotic cells and oxidized lipoproteins89,90. The former interaction has been
implicated in macrophage foam cell formation and the progression of atherosclerotic
plaques in murine models91.
With regard to vascular endothelial cells the CLESH (CD36, LIMPII, emp, SR-BI
Homology sequence 1) domain of membrane receptor CD36 has been shown to interact
with the type I repeats (TSRs) of several proteins including Thrombospondins-1 and -2
and vasculostatin81,92,93. This domain is prototypic of the CD36 gene family which
includes mammalian CD36, lysosomal integral membrane protein II (LIMPII), scavenger
receptor class B-I and Drosophila epithelial membrane protein (emp)94. This family is
defined by hydrophobicity, transmembrane domains with short cytoplasmic tails, an
uncleaved N-terminal peptide sequence, a single extracellular domain and a C-terminal
stop transfer domain95. Glutathione-S-Transferase (GST) fusion proteins were used to
identify the CLESH domain in CD36, specifically amino acids 93-120, and subsequently
in other family members, i.e. LIMPII81,94. Additional study is required to evaluate the
physiologic importance of TSP interaction with all members of the CD36 gene family.
Interaction of the CLESH domain of CD36 with the TSRs of TSP initiates an antiangiogenic signaling cascade in which CD36 interacts intracellularly with Src family
tyrosine kinase P59fyn with down-stream signaling to P38 mitogen-activated protein
kinase (MAPK) with accompanying caspase 3 like protease activation leading to
induction of apoptosis in microvascular endothelial cells, thereby inhibiting
angiogenesis70. This inhibition has been shown using in vitro and in vivo assays
previously mentioned in this manuscript70,72. Additionally, TSP signaling leads to the

14

upregulation of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAILR), Fas ligand and tumor necrosis factor receptor 177,96,97. Increases in TRAIL-R and Fas
ligand were shown to be CD36 dependent.
With regards to pathologic angiogenesis, little is known with regards to the role of
CD36. A recent study by Klenotic et.al. showed regulation of glioma tumor
angiogenesis and growth by TSR containing protein vasculostatin in a CD36 dependent
manner25. Direct regulation on endothelial cell migration was shown in vitro. Further,
vasculostatin was shown to directly interact with the CLESH domain of CD36 through
the use of GST fusion proteins. No evidence currently exists directly showing in vivo
regulation of tumor angiogenesis and growth by the TSR-CD36 signaling axis.
From these studies, we gain a picture of a cell membrance receptor involved in
numerous physiologic processes, primarily vascular in nature. Additionally, we highlight
areas requiring further study, including role of coreceptor expression in CD36-TSP
function, role of TSP binding to other CD36 gene family members and characterization
of the role of CD36-TSP interaction in pathologic angiogenesis, i.e. tumor angiogenesis
and progression.
HRGP
Histidine-rich Glycoprotein (HRGP), first described in 1972, is a 75 kDa soluble
plasma protein produced by the liver, which circulates at relatively high concentrations;
100-150 ug/ml98,99 (Figure 5). Additionally, HRGP is taken up by platelets and stored in
the alpha granules100. It has been shown to interact with numerous ligands, including
zinc, fibrinogen, vasculostatin, heparin, IgG and thrombospondin-198,101,102,103,104,105. As
such, HRGP has been implicated in diverse processes including immune function,
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thrombosis and angiogenesis.

Figure 5. HRGP structure. HRGP consists of two N-terminal cystatin like domains, a histidine rich
region flanked by two proline rich regions and a C-terminal domain. Disulfide linkages a shown by black
lines and glycosylation sites by bull’s-eyes (Parish 2005).

During normal immune response, antibodies recognize and complex with soluble
antigen forming immune complexes which are subsequently cleared from the body.
Inability to clear these complexes results in tissue deposition and the progression of
pathologic conditions such as rheumatoid arthritis. In vitro data has shown that HRGP
binds IgG and immune complexes, preventing insoluble immune complex formation,
thereby implicating it in clearance and deposition104,105,107. Further, intact HRGP and
fragments from the histidine rich region have been shown to possess anti-microbial and
fungal activities, Enterococcus faecalis and Escherichia coli, and Candida albicans
respectively108,109. This effect was mediated by HRGP binding of cell surface heparin
with subsequent membrane destabilization108. In vivo modeling with HRGP null mice
confirmed this effect109. Recent in vitro data has also implicated HRGP in the regulation
of adhesion and spreading. Conflicting results have been reported, in which HRGP
promotes or inhibits T cell adhesion110,111. Taken together these studies strongly support
a role for HRGP in immune function.
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HRGP has also been shown to be involved in thrombosis and fibrinolysis. As
mentioned above, HRGP is able to bind heparin. This binding has been shown to inhibit
the anti-thrombotic properties of heparin112. Further, HRGP binds fibrinogen, slowing
the rate of degredation102. In contrast, HRGP has been shown to enhance plasminogen
activation thereby speeding clot resolution113. Work utilizing HRGP null mice support
the later role for HRGP with null mice forming and resoving clots more rapidly114. Thus,
HRGP appears to promote clot formation and speeds its dissolution.
Aside from the thrombotic vascular function of HRGP, this protein has also been
shown to exert pro- and anti-angiogenic activities. Two groups have reported antiangiogenic functions by HRGP115,116. In vitro endothelial cell proliferation, migration
and tube formation assays and in vivo chorioallantoic chick membrane and matrigel
assays show inhibitory effects on angiogenesis. These studies make use of recombinant
peptides or artificially generated proteolytic fragments not shown to be generated in vivo.
Further they show localization of the anti-angiogenic properties of HRGP to the histidine
rich region. These effects require release of the histidine rich region by a yet unknown
mechanism. Plasmin presents as a possible candidate as it has previously been shown to
cleave HRGP117. In addition to the proposed anti-angiogenic effects of a portion of
HRGP, full length HRGP has been described as a pro-angiogenic molecule.
Work by our group has shown a pro-angiogenic role for HRGP mediated by a Cterminal CLESH homology domain. This domain, in similar fashion to the CLESH
domain of CD36 binds the TSRs of several proteins including thrombospondin 1 and 2
and vasculostatin92,103,118. In vitro assays including endothelial cell proliferation,
migration and tube formation show HRGP is able to inhibit the anti-angiogenic potential
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of TSR containing proteins. Similarly, in vivo matrigel, corneal micropocket and tumor
assays demonstrate HRGP inhibition of TSR inhibiton of angiogenesis. Tumor assays
relied on overexpression of HRGP in tumor cells. No studies have assessed the role of
ablation of HRGP in tumor angiogenesis and growth.
From these studies, we can appreciate the numerous roles of HRGP, most
vascular in nature. We additionally gain a feel for areas requiring further study. HRGP
appears to have a duality of angiogenic function whereby the intact molecule promotes
angiogenesis, while cleaved fragments may inhibit. Further study is required to show
generation of anti-angiogenic fragments in vivo and better clarify this duality.
Additionally, further work is required to assess the role of this protein in pathologic
angiogenesis, tumor growth and vascularization for example.
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CHAPTER II
ROLE OF CD36 – THROMBOSPONDIN - HISTIDINE-RICH GLYCOPROTEIN
AXIS IN TUMOR ANGIOGENESIS AND GROWTH
Hale, J.S., Jahnen-Dechent, W. and Silverstein, R. L.
*Departement of Biological, Geological and Environmental Sciences, Cleveland State University
and Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation
†IZKF BIOMAT, University Hospital, RWTH Aachen, Germany

Abstract
The angiogenic switch in the development of cancer is an important therapeutic
target. Work by our laboratory has established modulation of the interaction between
CD36 and Thrombospondin 1 (TSP-1) by Histidine Rich Glycoprotein (HRG) in the
regulation of angiogenesis. We have shown soluble HRG inhibits the anti-angiogenic
potential of the CD36-TSP-1 pathway through a decoy receptor function whereby TSP-1
is bound and sequestered. The type I repeats (TSR) of TSP-1 were shown to mediate
these interactions via a conserved domain in CD36 and HRG. We hypothesize the TSPCD36-HRG axis regulates vascularization and growth in the tumor microenvironment.
Lewis Lung Carcinoma (LL2) and B16F1 Melanoma tumor volumes were assessed in
wild type (WT) and hrg or cd36 null mice. LL2 tumor volumes were greater in cd36 null
mice and smaller in hrg null mice compared to WT. Immunofluorescent staining showed
increased vascularity in cd36 null vs. WT and WT vs. hrg null mice. No differences were
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observed with B16F1. Western analysis showed increased expression of TSP-1 by LL2
vs B16F1 cells. Exogenous TSR expression in B16F1 cells restored effects similar to
those obtained with LL2. These data suggest TSR-CD36 interaction leads to inhibition of
angiogenesis in the tumor microenvironment and HRG modulates this interaction.
Further, they suggest a mechanism by with insensitivity to TSR containing proteins may
be achieved.
Introduction
Angiogenesis is the physiologic process by which new vessels sprout from the
existing vasculature. In the normal adult setting, the vasculature is maintained in a
quiescent state through a balance of angiogenic inhibitors, such as thrombospondin
(TSP)-1, and inducers, such as vascular endothelial growth factor (VEGF). This balance
between pro and anti- angiogenic stimuli is important in homeostasis, in particular in
such conditions as pregnancy and wound healing. Loss of homeostatic balance resulting
in excessive or insufficient angiogenesis has been implicated in numerous diseased states
such as ulcerative colitis, diabetic retinopathy, obesity, psoriasis, rheumatoid arthritis,
stroke, coronary artery disease and cancer1.
It is well established that solid tumors will grow to 1-2mm by simple diffusion but
require a blood supply in order to expand further and metastasize2. To this end tumors
express pro-angiogenic substances such as basic fibroblast growth factor (bFGF) and
VEGF which recruit blood vessels to the lesion through the induction of microvascular
endothelial cell proliferation, migration and tube formation3. Previous studies have
shown ablation of pro-angiogenic phenotypes by endothelial cell membrane receptor
CD364,5. CD36, an 88 kDa class B scavenger receptor, is expressed on numerous
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vascular cell types including macrophages, platelets and microvascular endothelial cells.
CD36 recognizes at least three classes of extracellular ligands – oxidized phospholipids,
long chain fatty acids and proteins containing the so-called thrombospondin type I repeat
(TSR)6,7,8,9,10. These receptor-ligand interactions mediate effects in a cell type specific
manner. With regard to microvascular endothelial cells, a specific region of CD36
known as the CLESH domain interacts with high affinity with TSR domains of at least
three endogenous anti-angiogenic proteins - thrombospondins-1 and -2 and
vasculostatin8,9,10. These interactions initiate a complex intracellular signaling cascade
involving the Src family tyrosine kinase P59fyn and p38 mitogen-activated protein kinase
(MAPK) resulting in direct activation of caspase 3 like protease leading to induction of
apoptosis11. Additionally, CD36 mediated cell death in microvascular endothelial cells
has been reported to involve apoptotic receptors TNFR-1 and Fas12,13. These proapoptotic signals interrupt angiogenic responses induced by pro-angiogenic growth
factors, such as bFGF and VEGF.
Despite abundant evidence in mouse models and human tumors that downregulation of TSR-protein expression by genetic or epigenetic pathways in cancer cells
promotes angiogenesis and thereby promotes tumor growth and metastasis, little is
known whether modulating TSR interactions with its receptor, CD36, can influence
tumor behavior14,15,16,17. In data described in this chapter we tested the hypothesis that
genetic deletion of cd36 or of hrg, a gene encoding a circulating CD36 decoy protein,
would modulate tumor angiogenesis and tumor growth in syngeneic mouse tumor
implantation models.
Histidine-Rich Glycoprotein (HRG) is a 75 kDa protein synthesized by
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hepatocytes that circulates in plasma at relatively high concentrations (100-200 µg/ml)18.
There are also abundant stores of HRG in the alpha granules of platelets (~371 ng/109
platelets) that can be released into specific microenvironments in response to platelet
activation19,20. HRG is a modular protein that binds to proteoglycans, matrix proteins,
divalent cations, and coagulation proteins. It possesses a domain analogous to the
CLESH domain of CD36 that is able to bind TSRs of thrombospondin-1 and 2 and
vasculostatin8,9,10. It is through this domain that HRG acts as a soluble decoy receptor for
TSR domains, thereby blocking their binding to CD36 and regulating anti-angiogenic
signaling on microvascular cells. As such, we hypothesized that tumors formed in mice
lacking HRG will display increased CD36-TSP signaling resulting in decreased in
vascularization and tumor growth.
In the present chapter we show that genetic deletion of cd36 or hrgp in C57BL/6
mice effected tumor growth and vascularity. As predicted by our model, the effects were
in opposite direction, with increased tumor growth in cd36 null mice and decreased
growth in hrg null mice. Also we show that these effects depended on tumor cell
secretion of TSR-containing protein.
Methods
Materials
Mouse anti-VEGF receptor 2 antibody was from Cell Signaling Technology.
Rabbit anti- VE-Cadherin and TSP polyclonal antibodies were from Abcam. Goat antirabbit IgG Alexafluor 488 conjugate and DAPI Prolong Anti-fade mounting media were
from Invitrogen. Goat anti-rabbit horseradish peroxidase (HRP) was from Promega.
Tissue Tek Optimal cutting temperature compound (OCT) was from Fisher Scientific.
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Heparin, sucrose and paraformaldehyde were from Sigma.
Tumor Cells
Lewis Lung Carcinoma cells (LL/2) (CRL-1642) and B16F1 melanoma cells
(CRL-6323) were obtained from the ATCC and maintained in Dulbecco's Modified Eagle
Medium (Gibco) supplanted with 10% fetal bovine serum (Atlanta biologicals) and 0.5%
penicillin/streptomycin (10,000U/ml, Gibco). Cells were incubated at 37˚C, 95%
humidity and 5% CO2, grown in 75 cm2 cell culture flasks (Corning) and passaged twice
weekly. Cultures past 15 passages were not utilized. Stably transfected TSR-expressing
B16F1 melanoma cell lines were generated by transfecting the cells with pSecTag2
secretory plasmid (Invitrogen) into which a cDNA encoding the TSR domains of mouse
TSP-1 (amino acids 375-551) was cloned. Primers used for the cloning were
ATATTGAAGCTTGCCCAGCGACTCTGCTGAC and
ATATTGCTCGAGGTCCATCAATTGGGCAGTC. Transfection was done using the
Fugene 6 reagent (Promega) as per manufacturors directions. Transfected clones were
selected by antibiotic resistance using Zeocin (Invitrogen) at a concentration of 600
µg/ml. TSR expressing clones were identified by reverse transcription polymerase chain
reaction and confirmed by western analysis of serum free cultured media.
Animals
All experiments and handling of mice were approved by the Institutional Animal
Care and Use Committee (IACUC) of Cleveland Clinic. Mice were housed in a facility
fully accredited by AALAC and in accordance with all federal and local regulations. All
mouse strains used were of the same genetic background as the tumor cells - C57BL/6.
Generation of cd36 null and hrg null mice has previously been described21,22. Mice null
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for hrg were initially of the 129/B6 background and were backcrossed 10 generations
onto C57BL/6 background.
TSP-1 and TSR Expression Analysis
Secretion of TSP-1 or recombinant TSR peptide by mouse tumor cells was assessed after
culture in serum free media for 48 hours. Post culture media was collected and proteins
precipitated with trichloroacetic acid. Precipitated samples were washed twice with
acetone, resuspended in laemmli sample buffer and then electrophoresed on SDS-PAGE
(10%) gels under reducing conditions. Proteins were transferred on to polyvinylidene
fluoride (PVDF) at 250ma for 3 hours at 4C. Membranes were blocked with 5% milk in
0.1% triton tris buffered saline (TBS). Primary anti-TSP and secondary anti-rabbit HRP
antibodies were utilized at 1:1000 dilutions. Blots were developed using the ECL Plus
system (Fisher). Purified TSP 1 and HRGP were used as controls.
Syngeneic Tumor Implantation Studies
C57Bl/6, cd36 null or hrgp null mice were anesthetized with ketamine and
xylazine (IP, 50 mg/kg ketamine, 5 mg/kg xylazine). Lewis Lung Carcinoma (LL2),
B16F1 Melanoma or TSR-transfected B16F1 Melanoma cells were injected
subcutaneously onto the backs of eight week old male animals at a concentration of
50,000 cells/50 µl. Tumor volumes were assessed over 17 days using a standard formula
(V = L x W2 x 0.52), which assumes a hemi elliptical shape. Mice were anesthetized at
each time point. Following terminal measurement, mice were euthanized by CO2 and
perfused with heparin (10 U/ml) and 4% paraformaldehyde. Tumors were then resected,
incubated overnight in 15% sucrose and embedded in OCT. Samples were sectioned at a
thickness of 10µm. Overall cellularity and structure were evaluated by hematoxylin and
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eosin (H&E) staining. Blood vessel density was assessed by immunofluorescent staining
using anti-VEGFR2 or VE-Cadherin antibodies. Average vessel count/mm2 was
calculated from 6 fields of view per tumor taken at 200x magnification using a Leica
DM5500B automated upright microscope system.
Statistics
Power calculations were performed priori to determine group size using a
standard formula, n=2[(ua + ub)s/d]2, assuming variance of 20%, confidence of 95%, beta
error of 0.1 and standard error of 10%. Optimal group size was calculated to be 7
individuals. Differences between groups were calculated by Student’s unpaired T-test.
Outlying values were excluded using Grubb’s outlier test.
Results
Syngeneic Lewis Lung Tumors in Cd36 Null Mice Were Larger and More
Vascular Than in Wildtype
LL2 cells when injected into mice lacking cd36 produced tumors of greater size
than those injected into age and sex matched wildtype mice (Figure 6).

Figure 6. Cd36 deletion in mice enhances syngeneic tumor growth. Lewis Lung carcinoma cells (A)
or B16F1 melanoma cells
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These differences were statistically significant (P<0.05) at all time points at which
tumor volumes were measurable. Mean tumor volumes in cd36 null vs wildtype mice
were 21.0 mm3 vs 15.8 mm3 at day 7, 100.4 mm3 vs 52.1 mm3 at day 10, 213.6 mm3 vs
136.3 mm3 at day 14 and 316.2 mm3 vs 237.7 mm3 at day 17 respectively. Tumors
formed in cd36 null animals displayed increased areas of necrosis as evidenced by H&E
staining (data not shown) and greater vascularization (Figure 7). On average cd36 null
tumors contained 17.0 vessels/mm2 vs 12.2 vessels/mm2 in wildtype (P<0.05). These
data are consistent with our hypothesis that CD36 mediates an anti-angiogenic phenotype
resulting in decreased tumor vascularization and growth.

Figure 7. Cd36 deletion in mice enhances Lewis Lung tumor vascularity. (A) Lewis Lung tumors as in
Figures 6 were dissected, sectioned and examined by immunofluorescence microscopy using anti-VEGF
receptor antibody (green) to detect blood vessels. DAPI stained nuclei are blue. Magnification bars
represent 100µm. IgG control is shown in bottom panel as negative control. (B) Vessel densities measured
as vessels per mm2
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Syngeneic Lewis Lung Tumors in hrg null mice were smaller and less
vascular than in wildtype
When injected into mice lacking hrg, LL/2 tumors were smaller and less vascular
compared to those in wildtype mice (Figure 3A). Average tumor volume in hrg null vs
wildtype individuals were 10.4 mm3 vs 20.0 mm3 at day 7, 33.9 mm3 vs 49.1 mm3 at day
10, 93.9 mm3 vs 126.7 mm3 at day 13 and 189.6 mm3 vs 316.1 mm3 at day 17
respectively. Differences at all points day 7 and beyond were significant at P<0.05.
Tumors in hrg null mice displayed less necrosis (data not shown) and were characterized
by decreased vasculature compared with wildtype (Figure 4); on average hrg null tumors
contained 7.1 vessels/mm2 vs 13.6 vessels/mm2 in wildtype (P<0.05). These data are
consistent with our hypothesis that HRG modulates CD36-TSR anti-angiogenic
signaling.
Tumor cell TSR expression is required for regulation of syngeneic tumor
growth and vascularity by genetic manipulation of cd36 or hrg
In sharp contrast to the results seen with LL2 cells, implantation of B16F1
melanoma cells resulted in tumors of similar size (Figure 8 and 9) and vascularity (not

Figure 8. Cd36 deletion in mice enhances syngeneic tumor growth. Lewis Lung carcinoma cells were
injected in the backs of cd36 null or wild type C57BL/6 mice (50,000 cells/mouse). Tumor volumes were
assessed over 17 days following implantation. *P<0.05.
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Figure 9. Hrg deletion in mice suppresses syngeneic tumor growth. Lewis Lung carcinoma cells
(A) or B16F1 melanoma cells (B) were injected in the backs of hrg null or wild type C57BL/6 mice
(50,000 cells/mouse). Tumor volumes were assessed over 18 days following implantation. *P<0.05.

shown) regardless of genetic background of the host. We hypothesized that these
differences may relate to differing levels of TSR protein expression and indeed
immunoblot analysis of conditioned media from the tumor cell lines showed readily
detectable TSP-1 in the postculture media from LL2 cells, but not from B16F1 cells
(Figure 10A). We therefore generated stably transfected B16F1 cell lines that expressed
and secreted recombinant TSP-1 TSR domains. As shown in Figure 10B, Clone 11
expressed abundant TSR and was used for all further experiments. TSR transfection
restored responsiveness to the CD36/HRGP system. TSR expressing B16F1 cells
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Figure 10. Thrombospondin-1 secretion from cultured Lewis Lung and B16F1 melanoma cells. (A)
Lewis Lung (LL2) or B16F melanoma cells were cultured in serum free media for 24 hours (1d) at which
point proteins in post culture media (CM) were precipitated by TCA, separated under reducing conditions
by SDS/PAGE and analyzed by immunoblot using anti-TSP-1 antibody. TSP-1 monomers were detected at
170 kDa in the media conditioned by LL2 cells, but not B16F1 cells. Purified human HRG and TSP were
used as controls. (B) Conditioned media was collected from 4 different antibiotic resistant clones of TSR
transfected B16F melanoma cells and analyzed by immunoblot as in panel A. Clone 11 expressed
abundant anti-TSP reactive material at the appropriate molecular weight of recombinant TSR and was
utilized for subsequent tumor studies.

produced larger and more vascular tumors in cd36 null mice (Figures 11A, 7A left and
7B top) and smaller and less vascular tumors in hrgp null mice (Figures 11B, 7A right
and 7B bottom) when compared to age and sex matched wildtype controls. Average
tumor volume in cd36 null vs wildtype individuals were 27.8 mm3 vs 17.5 mm3 at day 8
(P=0.08); 67.7 mm3 vs 37.8 mm3 at day 11 (P<0.05); 170.5 mm3 vs 98.0 mm3 at day 14
(P<0.05); and 685.1 mm3 vs 394.7 mm3 at day 18 (p=0.06). On average cd36 null tumors
contained 16.3 vessels/mm2 vs 9.1 vessels/mm2 in wildtype (P<0.05). In the hrgp null
mice the average tumor volumes compared to wildtype were 5.8 mm3 vs 53.2 mm3 at day
11; 87.9 mm3 vs 255.3 mm3 at day 15; and 211.0 mm3 vs 651.7 mm3 at day 18. All of
these differences were significant at P<0.05. The tumors formed in hrg null animals
were more vascularized with on average 5.4 vessels/mm2 vs 10.1 vessels/mm2 in
wildtype (P<0.05). These data further support our hypothesis that CD36-TSR interaction
mediates an anti-angiogenic phenotype with modulation by HRG.
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Figure 11. TSR transfected B16F1 melanoma cells show enhanced tumor growth in cd36 null mice
and suppressed tumor growth in hrgp null mice. 50,000 cells from a stably transfected B16f1
melanoma cell line (Clone 11) were injected in the backs of cd36 null (A) or hrgp null (B) mice. C57Bl/6
mice were used as controls. Tumor volumes were assessed at timed points as in Figures 1 and 3. *P<0.05;
**P=0.08; ***P=0.06.
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Figure 12. TSR transfected B16F1 melanoma cells show enhanced tumor vascularity in cd36 null
Discussion
mice and suppressed tumor vascularity in hrgp null mice. (A) Tumors from TSR transfected B16F1
melanoma cells as in Figure 6 were dissected, sectioned and examined by immunofluorescence microscopy
using anti-VE-Cadherin antibody (green) to detect blood vessels. DAPI stained nuclei are blue.
Magnification bars represent 100µm. IgG control is shown in bottom panels as negative control. (B) Vessel
densities measured as vessels per mm2.

CD36- TSR signaling inhibits microvascular endothelial cell migration,
proliferation and tube formation in in vitro and in vivo models. Our group has shown that
this important endogenous anti-angiogenic system can be dampened by HRG, a protein
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with structural homology to CD36 that acts as a decoy for TSR. In vitro assays of
microvascular endothelial cell migration, proliferation, and tube formation; and in vivo
assays of angiogenesis in mouse corneal micropockets and implanted matrigel showed
that addition of exogenous HRG blocks TSP-1, TSP-2 and vasculostatin binding to CD36
and thereby inhibits TSR-mediated vascular cell responses9,10,23. HRG circulates in high
concentrations, can be released from activated platelets, and accumulates in perivascular
matrix; thus it is “poised” to serve an important role in regulating microvascular CD36TSR signaling in vivo24,25. This may have particular relevance to tumor angiogenesis
since HRG has been shown localize in the stromal connective tissue of human tumors,
including breast cancer and glioblastoma, and to mask the TSR domain of TSP10,23. The
potential importance of this system in carcinogenesis is supported by abundant data
showing that TSP1 has potent tumor suppressor activity and that genetic or epigenetic
down-regulation of TSP-1 expression is associated with progression of numerous human
cancers and enhanced tumor angiogenesis. We thus hypothesized that accumulation of
HRG in the tumor microenvironment would promote tumor growth, similar to loss of
tumor cell TSR expression, and that down-regulation of the receptor, CD36 would have
an opposite effect.
In the experiments described in this manuscript we used mouse genetic models to
provide direct evidence in support of this hypothesis. In the absence of CD36,
transplanted syngeneic tumors were larger and displayed increased vascularity, while in
the absence of HRG, tumors were smaller and displayed less vascularity. Importantly,
these host-mediated effects required production and secretion of TSR-containing protein
by the transplanted tumor. TSP-1 secreting Lewis Lung Cancer cells were sensitive to
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loss of CD36 or HRG, while TSP-1 negative B16F1 melanoma cells were not sensitive
unless they were stably transfected with a TSR-expressing plasmid. Our data suggest that
tumor cells could induce a state of functional TSR deficiency and hence promote
angiogenesis and tumor growth) by remodeling their micro-environment to downregulate microvascular CD36 expression and/or increase accumulation of HRGP
(discussed below). In regard to the former, we recently found that lysophosphatidic acid
(LPA) activates a protein kinase D-mediated signaling pathway in microvascular
endothelial cells that transcriptionally silences cd36 and thereby promotes angiogenesis26.
Since both tumor cells and inflammatory cells are potential sources of LPA, this could be
highly relevant to tumor biology.
HRG accumulation in tumor microenvironments would be expected to relate to at
least two processes known to promote tumor growth and metastasis – VEGF expression
and platelet activation27,28. In addition to promoting angiogenesis, VEGF is a potent
microvascular permeability factor that contributes to the “leaky” vasculature of tumor
beds29. In this milieu, plasma proteins such as HRG escape from the confines of the
vessel and permeate into the tumor bed. Similarly, platelet-tumor cell interactions have
been studied for many years and are known to promote both tumor growth and
thrombosis30. Platelet accumulation and activation in a tumor microenvironment would
have many effects, including release of both TSP-1 and HRG.
HRG was first characterized in 1978 as a molecule which bound heme and certain
metal ions31. Today, it is viewed as an adapter protein due to its multi-domain nature and
multiple ligand binding capacity, and has been implicated in diverse functions including
immunity, thrombosis, cell adhesion and angiogenesis32-34. The potential to develop
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HRG as a novel therapeutic target to regulate angiogenesis is complicated by reports
from two groups showing in contrast to our work, that HRG has anti-angiogenic
activity35,36. The mechanism for this activity has not been defined, but it is mediated by
the histidine-proline rich region of the protein. Our genetic models and abundant in vitro
and in vivo studies using intact, native HRG strongly support a pro-angiogenic role for
HRG in the presence of TSR proteins and did not show any anti-angiogenic activity, even
in the absence of TSR proteins. The most likely explanation for this apparent
controversy is that the anti-angiogenic activity requires proteolytic release of the
histidine/proline-rich domain. Whether there is an endogenous pathway to release the
domain has not been demonstrated, but precedent exists for proteolytic peptide fragments
having opposite biological activity than their “parent” protein37.
In summary, we showed in these studies that modulating tumor cell expression of
TSR proteins or expression in the non-transformed tumor microenvironment of CD36 or
HRG had significant impact on tumor angiogenesis and tumor growth. Numerous proand anti-angiogenic therapies are in clinical trials, among them ABT-510 and ABT-898,
which are peptide mimetics of the TSR domain of TSP-1. These compounds have shown
potential for treatment of cancer suggesting that targeting CD36 or HRG could present
effective alternative approaches to enhance or inhibit TSR action38-40.
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CHAPTER III

ROLE OF ZINC IN A DISINTEGRIN AND METALLOPROTEINASE WITH
THROMBOSPONDIN MOTIFS 1 (ADAMTS1) PROCESSING OF
THROMBOSPONDIN 1
Hale, J. S.* and Silverstein, R. L.*
*Department of Biological, Geological and Environmental Sciences, Cleveland State University and Department of
Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation

Abstract
Thrombospodin 1 (TSP) is a well characterized vascular regulating protein. The
anti-angiogenic effects of TSP have been localized to the type I repeats (TSRs).
Additionally, vasodilatory and dendritic cell mediated T cell modulatory effects have
been localized to the C-terminal domain. Previous work has demonstrated TSP cleavage
by ADAMTS1, with release of anti-angiogenic peptides. We propose zinc mediated
modulation of TSP cleavage by ADAMTS1. Upon addition of zinc to the system, an
additional TSP cleavage site is generated, from those previously described. This site is
located in the C-terminal domain of TSP, thereby presenting a method of regulating
CD47 interaction. Regulation of this interaction may have implications in vasodilation,
angiogenesis and immune function regulation.
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Introduction
Remodeling of the extracellular matrix by matrix metalloproteases is vital to
numerous homeostatic processes including angiogenesis. The ADAMTS (a disintegrin
and metalloproteinase with thrombospondin motif) family of extracellular, zinc
dependent proteases consists of 19 members, all of which contain the type I repeats
(TSRs) of Thrombospondin I (TSP)1. Theses enzymes are involved in collagen
processing, cleavage of matrix proteoglycans, thrombosis and inhibition of angiogenesis2.
With regard to inhibition of angiogenesis, ADAMTS 1 and 8 have been shown to
inhibit vascular endothelial growth factor (VEGF) and basic fibroblast growth factor
(bFGF) induced endothelial cell proliferation in vitro and angiogenesis in the in vivo
corneal micropocket and chick chrioallantoic membrane assays3. ADAMTS1 mediates
these effects via binding bFGF and VEGF4,5. Additionally, work by Dr. Arispe has
demonstrated that ADAMTS1 may cleave thrombospondin 1 and 2 in such a manner that
protein releases three monomers each containing the type one repeats6. The proteolytic
cleavage of thrombospondin 1 and 2 is proposed as a mechanism by which the antiangiogenic potency of matrix bound thrombospondin may be modulated. Here after we
will focus on TSP, however it should be noted that many of the anti-angiogenic
properties cited are shared with thrombospondin 2 as both proteins are structurally
similar, containing the type I repeats.
TSP is a 450 kDa trimeric multidomain matricellular glycoprotein. It was the first
endogenous anti-angiogenic molecule identified. TSP, in vitro, inhibits microvascular
endothelial cell proliferation, migration and tube formation in response to basic fibroblast
growth factor (bFGF) and vascular endothelial growth factor (VEGF), through the
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induction of apoptosis7,8. Further, TSP inhibits vascularization, in vivo, in response to
pro-angiogenic stimulus as demonstrated by corneal micropocket and subcutaneous
matrigel assays7,9.
The anti-angiogenic effects of TSP have been localized to the type I repeats
(TSRs). In vitro treatment of microvascular endothelial cells with recombinant TSR has
been shown to induce apoptosis10. Additionally, TSR treatment, in vivo, effectively
inhibits tumor growth and vascularization10,11.
In addition to the anti-angiogenic role localized to the TSRs, TSP also mediates
vascular biology via its C-terminal domain. Interaction of the C-terminal domain of TSP
with membrane receptor CD47 on dendritic cells suppresses cytokine production,
decreasing T-cell activation12,13. CD47 was further shown to be necessary for TSP
inhibition of NO signaling, which mediates vessels dilation via vascular smooth muscle
cells, allowing for increased fluid extravasation into the surrounding tissues14.
Previous study of the cleavage of TSP by ADAMTS1 has excluded an important
heavy metal, zinc, in the regulation of protease function. We hypothesize zinc modulates
ADAMTS processing of TSP. To this end we utilized an in vitro physiologic system in
the presence and absence of zinc to assess the role off this heavy metal. We show that
addition of zinc induces additional processing of TSP at the C-terminal domain.
Materials
Thrombospondin Isolation
One unit, 250 cc, of outdated concentrated platelets was obtained from the
Cleveland Clinic Blood Bank. Samples were spun at 200 g to remove contaminating red
blood cells. Platelets were then pelleted at 900 g and resuspended in Broekmanns buffer,
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repeated 3 times to wash. Pellets were combined and resuspended in a final volume of
15ml 20mM Tris 150mM NaCl pH 7.6 buffer and Calcium added to a final concentration
of 2mM. Platelets were stimulated with 3 U/ml thrombin, followed by hirudin (6 U/ml)
inhibition. Samples were then spun at 20,000 g and supernatant applied to a 1 ml heparin
column. TSP was eluted at 0.45M NaCl. Elution fractions were run on denaturing gels
and positive fractions combined and diluted 1:3 in 20mM Tris, pH 7.4. Sample was then
applied to a 1 ml mono Q anion exchange column and TSP was eluted over 0-0.8M NaCl
gradient (~0.6M). Elution fractions were run on denaturing gels and positive fractions
quantified for protein concentration.
ADAMTS1 digestion of Thrombospondin
Standard digestions were carried out under physiologic conditions in pH 7.4
buffer containing 20mM Tris, 150 mM NaCl, 10mM CaCl and 15 µM ZnCl. Following
optimization, 2µg purified TSP was digested with 400ng recombinant ADAMTS1 (R&D
Systems) overnight at 37C, a 1:5 ratio. Calcium and Zinc were chelated from digestion
buffers with EGTA and Zincon respectively. Following digestion, samples were run on
10% reducing gels and coomassie stained.
Sequence Analysis
Sequence analysis was carried out by the Mass Spectroscopy Core of the
Cleveland Clinic Foundation. Proteins were excised from reducing poly-acrylamide gels
and destained in 50% ethanol, 5% acetic acid. Excised bands were the reduced with
dithiothreitol, iodoacetamide alkylated and trypsin digested overnight. Resulting
peptides were extracted and dried to less than 30 µl. Liquid chromatography-mass
spectroscopy was performed using the Thermofisher LTQ ion trap mass spectrometer
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with a 8cm x 75 µm id Phenomenex Jupiter C18 reverse phase capillary chromatography
column. Peptide samples were inected using an Eksigent nanoflow liquid
chromatography system and eluted with an acetonitrile-0.05M acetic acid gradient.
Generated collisionally induced dissociation (CID) spectra were used to perform Mascot
NCBI database searches.
Results
ADAMTS1, under physiologic conditions cleaves TSP N-terminally, with
decreases in detectable peptides prior to amino acid 313 (Figure 13, 14-5). This site is
located in the disulfide linker region (Figure 15). Addition of zinc to digestion buffers
resulted in more efficient N-terminal cleavage and the generation of an additional

Figure 13. ADAMTS1 generates multiple fragments of Thrombospondin 1. ADAMTS1 alone (lane
1), Thrombospondin 1 alone (lane 2), Thrombospondin cleavage by ADAMTS1 (lane 3). In physiologic
buffer conditions ADAMTS1 processing of Thrombospondin 1 yields 2 fragments (1 & 2, lane 3).
Fragment 1 corresponds to a N-terminally truncated form of Thrombospondin 1, prior to amino acid 313.
Fragment 2 corresponds to a C-terminally truncated form of Thrombospondin 1, after amino acid 1054.
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Figure 14. ADAMTS1 utilizes calcium and zinc in Thrombospondin 1 cleavage. ADAMTS1
requires zinc and to a lesser extent calcium in the generation TSP fragments. Requirement for metal
ions, to agreater degree zinc, is greater for C-terminal cleavage of TSP. EGTA and Zincon were used
to chelate calcium and zinc respectively from the digestion buffers. Lane 1 TSP with EGTA alone,
Lane 2 TSP with Zincon alone, Lane 3 TSP with EGTA and Zincon, Lane 4 ADAMTS1 alone, Lane 5
TSP alone, Lane 6 TSP digestion by ADAMTS1 at 1:5 ratio, Lane 7 TSP digestion with EGTA, Lane
8 TSP digestion with Zincon, Lane 9 TSP digestion with EGTA and Zincon.

Figure 15. ADAMTS1 generated fragments of Thrombospondin 1. The ADAMTS1 cleavage
sites, indicated by blue arrows, on an intact monomer of Thrombospondin 1. Cleavage site 1 is
located in the disulfide linker region. Cleavage site 2 is located in the globular C-terminal domain.

fragment (Figure 13, 14). This fragment corresponds to a C-terminal cleavage after
amino acid 1054, as identified by decrease peptide detection (Figure 16, 17). This site is
located within the globular C-terminal domain of TSP (Figure 15). Chelation of calcium
reduced N-terminal and C-terminal cleavage of TSP by ADAMTS1. Chelation of zinc
reduced N-terminal cleavage and abolished C-terminal cleavage of TSP by ADAMTS1
(Figure 14).
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Figure 16. ADAMTS1 produces N and C terminal cleavage of Thrombospondin 1. Molecular
weight ([M+H]+), peptide sequence and amino acid positions are given from left to right. Mass spec
analysis identified multiple peptide matches to Thrombospondin 1 in the full length protein, 11 shown
above (column full). ADAMTS1 cleavage of TSP in the presence of calcium (Band 1) resulted in Nterminal cleavage with complete absence of a small N-terminal peptide (amino acids 21-41).
ADAMTS1 cleavage of TSP in the presence of calcium and zinc (Band 2) resulted in more efficient Nterminal cleavage with absence of N-terminal peptides up to amino acid 313. Additionally, addition of
zinc to the digestion buffer induced C-terminal cleavage of TSP with peptides missing after amino acid
1054.

Figure 17. ADAMTS1 N and C terminally cleaves Thrombospondin 1. More sensitive
quantification of identified peptides are shown normalized to full length TSP (H(truncated)/H(full)). All
peptides were detected in each digestion sample, possibly owing to carry over contamination as the same
column was used. ADAMTS1 cleavage of TSP in the presence of calcium (Band 1) resulted in
reduction of N-terminal peptides prior to amino acid 313 as compared to abundance in full length TSP.
ADAMTS1 cleavage of TSP in the presence of calcium and zinc (Band 2) resulted in increased
reduction of N-terminal peptides prior to amino acid 313 and after amino acid 1054 as compared to full
length TSP.
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Discussion
ADAMTS1 has previously been shown to inhibit angiogenesis in vitro and in
vivo3,4. Work by Iruela-Arispe has previously shown that this effect may be related to
ADAMTS1 processing of thrombospondins 1&26. It was shown that cleavage of TSP
occured between amino acids 311 and 312, similar to our current findings with regards to
N-terminal cleavage. Further, TSP cleavage by ADAMTS1 was observed in vivo using
wound healing models and purified proteolytically released monomers were shown to
inhibit endothelial cell proliferation in vitro. Thus, it was hypothesized that this may
present as a mechanism to release the anti-angiogenic poteintial of matrix bound TSP in
the inflammatory setting or serve as an amplification strategy by releasing the individual
monomers from the intact TSP trimer.
The ADAMTSs belong to the adamalysin subfamily of the metzincins, or zinc
dependent proteases15. As such, the current work presented here builds on that
previously described, assessing the role of zinc in ADAMTS1 processing of TSP. We
show that the addition of physiologic concentrations of zinc16 lead to additional cleavage
of TSP by ADAMTS1. Zinc addition results in cleavage in the C-terminal domain of
TSP, with inhibition upon chelation. Therefore these results appear to be specific to zinc.
This novel processing of TSP highlights the importance of zinc in ADAMTS1 function
and presents a mechanism by which the interaction of the C-terminal domain of TSP with
membrane receptor CD47 may be regulated. Additional, more stringent sequencing is
needed to specifically identify the C-terminal cleavage site.
The vascular effects of TSP have previously been shown to involve CD36 and
CD4714,17. TSP inhibition of nitric oxide mediated blood vessel dilation requires CD47
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interaction with its C-terminal domain. Alternatively, CD36-TSP interaction has been
shown to inhibit growth bFGF and VEGF induced angiogenesis. This interaction is
localized to the TSRs of TSP. Thus, zinc mediated C-terminal cleavage of TSP by
ADAMTS1 presents a mechanism by which CD47-TSP interaction may be inhibited
allowing for CD36-TSP signaling to predominate, thus shifting focus from vascular tone
to angiogenesis. It is also possible that C-terminal cleavage of matrix bound TSP is
required for release from the cell surface, with subsequent N-terminal cleavage allowing
for a 2 stage amplification of cell bound anti-angiogenic stores. Additional study is
required to address these hypotheses.
Alternatively, we hypothesize C-terminal cleavage of TSP by ADAMTS1 may
occur at sites of inflammation, where matrix metalloprotease levels are known to be
elevated. C terminal cleavage may reduce inhibition of vessel dilation by CD47-TSP
interaction. This may present a mechanism by which the inflammatory setting may be
modulated, allowing for increased edema and immune cell extravasation from vessels.
Further work is required to address this hypothesis.
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CHAPTER IV

DISCUSSION
The studies presented in this manuscript examine the importance of the
angiogenic switch in the progression of cancer and more specifically the role of TSRCLESH interaction and processing of TSP by ADAMTS1. The following section
highlights the importance of the findings presented and discusses avenues of research
which warrant additional inquiry.
The field of anti-angiogenesis has expanded from concept to patient treatment in
the forty years since Judah Folkman was told “anti-angiogenic molecules existed only in
his mind”. Numerous angiogenic inhibitors have been identified and are now under
clinical investigation for the treatment of cancer. These include naturally occurring
compounds, such as those found in green tea and occurring naturally in the body as well
as synthetically manufactured molecules. Additionally, drugs currently on the market
have been rediscovered as anti-angiogenic therapies.
As discussed previously in this manuscript, the anti-angiogenic effects of TSP
have been localized to the TSRs. Based on these studies three mimetic peptides from this
region have been designed and are currently under investigation for the treatment of
cancer; ABT-510, ABT-898 and ABT-5261,2. ABT-526 is the original TSR mimetic
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peptide, off of which ABT-510 and ABT-898 were designed. These compounds have
shown increased solubility, potency and slowed clearance compared with ABT-526
(ABT-898 > ABT-510 > ABT-526). Of these, ABT-510 has progressed through phase II
clinical trials, showing limited efficacy3. Unfortunately, tolerance and conflicting reports
with regards to efficacy of these compounds in cancer treatment have been obtained. As
such, better characterization of the mechanisms underlying their action is required.
Interaction of the TSRs of TSR containing proteins with the CLESH domain of
membrane receptor CD36 initiates an anti-angiogenic cascade resulting in the apoptosis
of vascular endothelial cells thereby inhibiting angiogenesis. In previous studies, TSR
binding to the CLESH domain of CD36 has been shown to inhibit angiogenesis4,5,6,7. We
for the first time show direct regulation of tumor angiogenesis and growth by the TSRCD36 pathway. Past studies have also shown the ability of HRGP, a soluble CLESH
homology domain containing protein, to sequester TSR containing proteins, preventing
the initiation of the anti-angiogenic CD36 signaling cascade. We verify this effect in the
tumor microenvironment showing direct regulation of tumor growth and angiogenesis.
The CLESH domain may therefore serve as an important therapeutic target in the
inhibition of cancer angiogenesis. Additional studies utilizing soluble CLESH peptides as
well as CLESH binding antibodies and small molecule activators in the regulation of
angiogenesis are required. Activation of CD36 signaling or inhibition of HRGP-TSR
binding by these compounds may allow for potent inhibition of angiogenesis.
As discussed earlier, ADAMTS1, a TSR containing, protein has been shown to
process TSP, releasing anti-angiogenic monomers from the intact trimer. Work by Dr.
Iruela-Arispe further showed processing in vivo during wound healing, with ADAMTS1
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null mice displaying increased vessel density8. Work presented here built on these
studies, showing additional C-terminal processing of TSP by ADAMTS1 with the
addition of zinc to digestion reactions. Further, we hypothesize that C-terminal
processing may be required for the release of cell matrix bound TSP.
Thus, it is possible that ADMATS1 processing of TSP allows for a 2 step
amplification of its anti-angiogenic potential; first releasing the TSP trimer from the
extracellular matrix and second amplifying its inhibitory potential by cleaving the trimer
into monomers. This proposed mechanism for increased anti-angiogenic potential by
TSP may allow for the modulation of cancer angiogenesis. Treatment with exogenous
ADAMTS1 may mediate increased TSR release from endogenous TSP, allowing for
increased anti-angiogenic potential. Further investigation is required to evaluate the
potential of this strategy.
The studies presented in this manuscript meet the need to better characterize the
processes promoting the anti-angiogenic effects of TSR containing molecules, of which
41 have been identified in humans9. We should however not overlook the “flip-side” of
the coin, instances in which induction of angiogenesis may be beneficial. One of the
early studies utilizing pro-angiogenic therapy was in the treatment of coronary heart
disease10. Following coronary artery bypass surgery patients were locally injected with
bFGF. Those injected with bFGF showed increased neovascularization of grafted tissue.
Pro-angiogenic therapy has now been employed in the treatment of several pathologic
conditions including wound healing, atherosclerosis and cardiovascular ischemia. Thus,
inhibition of TSR release and ligation with CD36 may allow for the development of
novel pro-angiogenic induction. To this end, exogenous CLESH domain or intact HRGP
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administered systemically may allow for the promotion of angiogenesis. Additional
study is needed to explore this exciting new possibility.
In conclusion, TSR mediated anti-angiogenesis holds great promise in the
angiogenic treatment of cancer. Further insight into the relationship between this domain
and the CLESH domain of interacting partners such as CD36 and HRGP will allow us to
increase the effectiveness of TSR focused compounds. Additionally, a better
understanding of the physiologic processing of intact TSP may provide the opportunity to
increase or inhibi the anti-angiogenic capacity of endogenous stores of TSP. Thus, the
field of angiogenic inhibition by the TSRs of TSP still has many new and intriguing
insights to provide.
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